CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病

Abstract

Recommended Article

Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized Study The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008